Myeloma

Christi Shaw may have changed her life this spring, switching from being a pharmaceutical exec to a caregiver, but one thing has stayed the same: her determination to fight cancer.

A new triplet for treating multiple myeloma may be then next new standard, according to Antonio Palumbo.

While the use of Kyprolis (carfilzomib), Pomalyst (pomalidomide) and KPd (dexamethasone) to treat some myeloma patients was "promising," researchers said that they will give the combination a closer look.

When Darzalex was added to Velcade and dexamethasone, patients with relapsed multiple myeloma had a reduced risk of disease progression or death, according to a recent phase 3 trial.

Patients with heavily pretreated relapsed/refractory multiple myeloma showed increased progression-free survival and overall survival rates with isatuximab.

Patients with multiple myeloma live longer without their disease progressing if they get a stem cell transplant, compared with patients who received chemotherapy alone.

Our director of patient education, Marty Murphy, discusses his trip for the Moving Mountains for Multiple Myeloma campaign with WRAL.

While there have been many recent groundbreaking advances in treating myeloma, Kenneth C. Anderson is optimistic that the future holds even more promise.

A recent phase 3 trial is exploring the question of whether or not smoldering multiple myeloma needs treatment.

A new three-drug combination is proving successful for patients with relapsed/refractory multiple myeloma, according to a phase 3 study.

For some patients with myeloma, new targeted drugs may be an alternative to stem cell transplant.

About 24 years ago, Jim Bond was handed a stage 3 myeloma diagnosis and told to start checking things off his bucket list. Little did doctors know, but one of the top items on that list was survival

Four new drugs were approved in 2015 to treat multiple myeloma, and Sundar Jagannath is optimistic about the coming years.

Rafat Abonour, MD, professor of Medicine, pathology, and laboratory medicine at Indiana University, discusses the importance of raising awareness about multiple myeloma and his Miles for Myeloma initiative.

Mary Bohn, RN, OCN, a nurse at Froedtert Hospital in Milwaukee, Wisconsin, discusses the landscape and side effects of treatment for patients with multiple myeloma.

Ryan Cohlhepp, from Takeda Oncology, discusses the accomplishments of the Moving Mountains for Multiple Myeloma team. Cohlhepp, along with other members of the team, were honored at our 2016 Multiple Myeloma Heroes event.

Jeff Goad and his wife, Ramona Biliunas, discuss why the climbed Mount Kilimanjaro as part of the Moving Mountains for Multiple Myeloma team. Jeff was also one of our 2016 Multiple Myeloma Heroes.